# A Study of IBI3032 in Chinese Healthy Subjects

> **NCT07134127** · EARLY_PHASE1 · COMPLETED · sponsor: **Innovent Biologics Technology Limited (Shanghai R&D Center)** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** placebo
- **DRUG:** IBI3032

## Key facts

- **NCT ID:** NCT07134127
- **Lead sponsor:** Innovent Biologics Technology Limited (Shanghai R&D Center)
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-29
- **Primary completion:** 2025-10-07
- **Final completion:** 2025-10-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07134127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07134127, "A Study of IBI3032 in Chinese Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07134127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*